AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25211369
Drug: ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor and acetylsalicylic acid (ASA) in combination with dabigatran (150 mg bid)
Trial: 25211369
Drug: ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor and acetylsalicylic acid (ASA) in combination with rivaroxaban (20 mg od)
Trial: 25211369
Drug: ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor and acetylsalicylic acid (ASA) in combination with phenprocoumon (INR 2.0‐3.0)
Trial: 17627484
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg nightly for 4 weeks)
Trial: 17627484
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically appearing tablet nightly for 4 weeks)
Trial: 16235184
Drug: Thrice-weekly trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly trimethoprim-sulfamethoxazole (TS) for 12 weeks
Trial: 11149033
Drug: Dopamine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine + Mannitol (0.25 g/kg every 12 hours for 2 postoperative days)
Trial: 11149033
Drug: Dopamine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine + Furosemide (1 mg/kg every 12 hours for 2 postoperative days)
Trial: 9489083
Drug: Nisoldipine coat
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine coat core (CC) 10 mg o.d.
Trial: 9489083
Drug: Nisoldipine coat
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine coat core (CC)
Trial: 7691765
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate in non-thrombolytic group
Trial: 7691765
Drug: Ongoing fibrinolytic
RxNorm normalized name: Ongo-Fin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing fibrinolytic therapy
Trial: 27807527
Drug: General physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General physical therapy group (PTG, n=23)
Trial: 16061589
Drug: Additional analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional analgesia with morphine
Trial: 12370838
Drug: Glipizide GITS
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glipizide GITS monotherapy (20 mg/d)
Trial: 12370838
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy (2.5 g/d)
Trial: 12370838
Drug: Monotherapy (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (either glipizide GITS or metformin)
Trial: 7672959
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation therapy (n = 8)
Trial: 2149882
Drug: Remoxipride (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (high doses: 300-600 mg daily)
Trial: 7023649
Drug: Weekly methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly methotrexate
Trial: 7023649
Drug: Biweekly methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Biweekly methotrexate with leucovorin rescue (ML)
Trial: 7023649
Drug: Biweekly ML
RxNorm normalized name: Biweekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly ML combined with cyclophosphamide and cytosine arabinoside (MLCC)
Trial: 23484176
Drug: 35% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% hydrogen peroxide bleaching gel
Trial: 16033337
Drug: Apple juice
RxNorm normalized name: apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple juice (glucose 28 g in 250 ml) administered at 06:00‐06:30 am
Trial: 2100642
Drug: Pliva 60
RxNorm normalized name: theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pliva 60 diltiazem preparation
Trial: 2100642
Drug: Pliva 90
RxNorm normalized name: theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pliva 90 diltiazem preparation
Trial: 2100642
Drug: Aldizem 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldizem 90 diltiazem preparation
Trial: 6800954
Drug: Group Y
RxNorm normalized name: Neisseria meningitidis group Y Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Y vaccine
Trial: 6800954
Drug: Group W135
RxNorm normalized name: Neisseria meningitidis serogroup W135 conjugated Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group W135 vaccine
Trial: 6800954
Drug: Group Y-W135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Y-W135 combined vaccine
Trial: 6800954
Drug: Monovalent vaccine
RxNorm normalized name: rotavirus, live, monovalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent vaccine (50 micrograms)
Trial: 6800954
Drug: Divalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalent vaccine (100 micrograms)
Trial: 30157894
Drug: SWIS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SWIS treatment (pre‐post‐follow‐up)
Trial: 22205203
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 35 mg/m(2) in < 65 years group
Trial: 22205203
Drug: Bortezomib 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.0 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 20 mg/m(2) in ≥ 65 years group
Trial: 22205203
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Bortezomib, Gemcitabine, Liposomal Doxorubicin)
Trial: 20631326
Drug: Zinc administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc administration (10 mg/d for children 2-11 months and 20 mg/d for children ≥ 12 months) for 14 days
Trial: 20631326
Drug: Zinc administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc administration
Trial: 18551467
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Trial: 18551467
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Trial: 18551467
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (0.3 g extract/250 ml) with 5 mg folic acid
Trial: 18551467
Drug: Water (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (reference drink) with 0.4 mg and 5 mg folic acid
Trial: 17002050
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy regimen '2b' (isoniazid, rifampicin, pyrazinamide, ethambutol, fluoroquinolone (ofloxacin, ciprofloxacin, levofloxacin), and canamycin (amikacin))
Trial: 17002050
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy regimen '2a' (isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin)
Trial: 17002050
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy regimen '2b'
Trial: 17002050
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy regimen '2a'
Trial: 1706562
Drug: Clemastine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine 4 mg + Cimetidine 400 mg i.v. 15 min before implantation
Trial: 6765509
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of triamcinolonehexacetonide (TH)
Trial: 6765509
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of the combination betamethasone acetate and betamethasone disodiumphosphate (BM)
Trial: 28685396
Drug: Bupropion HCl
RxNorm normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion HCl immediate release (IR) 75 mg
Trial: 28685396
Drug: Bupropion HCl
RxNorm normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion HCl sustained release (SR) 100/150 mg
Trial: 28685396
Drug: Bupropion HCl
RxNorm normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion HCl extended release (ER) 150/300 mg
Trial: 24238630
Drug: Web-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based treatment program
Trial: 17885577
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment (open-label and double-blind)
Trial: 7874154
Drug: ATP‐E (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP‐E (0.2 g.kg‐1.day‐1)
Trial: 3282867
Drug: Sustained action
RxNorm normalized name: TABLET, BUCCAL SUSTAINED ACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained action tiaprofenic acid 600 mg once daily
Trial: 3282867
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release indomethacin 75 mg once daily
Trial: 31811952
Drug: Biofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback treatment (2-3 sessions combined with daily exercise)
Trial: 31811952
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber supplementation (3.5 g plantago ovata per day)
Trial: 9579209
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of meglumine antimoniate (MA; 15 mg Sb/kg.day) on 6 days/week for 12 injections.
Trial: 9579209
Drug: Intralesional administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional administration of meglumine antimoniate (MA; 0.2‐0.8 ml/lesion) every other day for 30 days.
Trial: 3300518
Drug: Clonidine (0.0075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.0075 mg/kg/day)
Trial: 3300518
Drug: Clonidine (0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.015 mg/kg/day)
Trial: 3300518
Drug: Clonidine (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (twice a day)
Trial: 3300518
Drug: Clonidine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (in patients receiving neuroleptic agents)
Trial: 3300518
Drug: Clonidine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (low dose vs high dose)
Trial: 30001903
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (manual therapy + motor control exercises + inspiratory muscle training)
Trial: 27296490
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral methotrexate weekly
Trial: 27296490
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g mycophenolate mofetil twice daily
Trial: 24497828
Drug: IL-7 administration
RxNorm normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-7 administration (recombinant human IL-7 at 20 µg/kg, three subcutaneous injections)
Trial: 24497828
Drug: IL-7 administration
RxNorm normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-7 administration
Trial: 24349532
Drug: IL‐18 ‐137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐18 ‐137 polymorphism (G/C heterozygotes)
Trial: 24349532
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to oral cancer-related environmental risk factors (areca, alcohol, tobacco)
Trial: 24349532
Drug: IL‐18 ‐137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐18 ‐137 G/C alleles
Trial: 18237588
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment at cuff pressures of 75 mm Hg
Trial: 18237588
Drug: Enhanced external
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced external counterpulsation (EECP) and Sham treatment
Trial: 12627927
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) for outpatients
Trial: 12627927
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin for inpatients
Trial: 11802676
Drug: Medication Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Placebo
Trial: 7845799
Drug: Rate augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate augmentation factor set to low with medium speed of response
Trial: 7845799
Drug: Rate augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate augmentation factor set to medium with fast speed of response
Trial: 7845799
Drug: Rate augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate augmentation factor set to high with fast speed of response
Trial: 7845799
Drug: Rate augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate augmentation factor
Trial: 29631810
Drug: sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib plus hepatic arterial infusion chemotherapy (cisplatin 20 mg/m2 on days 1 and 8 and fluorouracil 330 mg/m2 continuously on days 1-5 and 8-12 of every 28-day cycle)
Trial: 29631810
Drug: sorafenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib monotherapy (400 mg orally twice daily)
Trial: 29631810
Drug: sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib plus hepatic arterial infusion chemotherapy
Trial: 29631810
Drug: sorafenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib monotherapy
Trial: 26451086
Drug: Generic MT
RxNorm normalized name: MT-0169
DrugBank: MT-0169 (DB17430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic MT 5 mg chewable tablets
Trial: 26451086
Drug: Branded Singulair(®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded Singulair(®) pediatric 5 mg chewable tablets
Trial: 24553281
Drug: 10 percent
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 percent CPP-ACP cream
Trial: 8941023
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of rt-PA
Trial: 1357924
Drug: Protopam chloride
RxNorm normalized name: Protopam Chloride
DrugBank: Pralidoxime (DB00733)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protopam chloride (1,000 mg intravenously)
Trial: 1357924
Drug: Protopam chloride
RxNorm normalized name: Protopam Chloride
DrugBank: Pralidoxime (DB00733)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protopam chloride (oral and parenteral administration)
Trial: 1357924
Drug: Protopam chloride
RxNorm normalized name: Protopam Chloride
DrugBank: Pralidoxime (DB00733)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protopam chloride (large doses)
Trial: 30857448
Drug: Oral leukoplakia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leukoplakia (OL) patients
Trial: 24373019
Drug: Imidafenacin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin 0.1 mg twice daily (group A)
Trial: 24373019
Drug: Propiverine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 20 mg once daily (group B)
Trial: 22406705
Drug: Lycopene 8
RxNorm normalized name: multivit,calcium,minerals/iron fumar/folic ac/vit K/lycopene 8 mg iron-200 mcg-60 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene 8 mg/day for 8 weeks
Trial: 18077928
Drug: gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemifloxacin 320 mg/tablet (test product)
Trial: 18077928
Drug: factive 320
RxNorm normalized name: Factive 320mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: factive 320 mg/tablet (reference product)
Trial: 10575269
Drug: BCG (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (81 mg, 6 weekly instillations)
Trial: 15643181
Drug: Epirubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (50 mg, 8 weekly instillations)
Trial: 2105638
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 1,200 mg/d for 16 weeks
Trial: 2105638
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (observation without changes in prescription)
Trial: 6975168
Drug: Cotrimoxazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (80 mg trimethoprim and 400 mg sulfamethoxazole)
Trial: 6975168
Drug: Co-tri-famole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-tri-famole (80 mg trimethoprim and 400 mg sulfamoxole)
Trial: 23919432
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (1 μg·kg(‐1))
Trial: 23181640
Drug: Hyaluronidase (HAase)
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase (HAase) injection (20,000 turbidity-reducing units)
Trial: 19261295
Drug: Sapropterin dihydrochloride,
RxNorm normalized name: Sapropterin Dihydrochloride, 100 mg oral tablet, soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin dihydrochloride, 20 mg/kg/d for 10 weeks
Trial: 8265301
Drug: Sn-mesoporphyrin (SnMP)
RxNorm normalized name: Sn Mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sn-mesoporphyrin (SnMP) at a dose of 6 mumol/kg body weight
Trial: 21357906
Drug: Oral prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone, 25 mg/d for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Trial: 21357906
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Trial: 9039155
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium supplementation (1500 mg of calcium per day)
Trial: 8341042
Drug: .85 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .85 g/kg alcohol
Trial: 3669071
Drug: Treatment choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment choice (parents allowed to choose between two antibiotics)
Trial: 3669071
Drug: Treatment choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment choice (parents not allowed to choose)
Trial: 26035186
Drug: Vortioxetine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (both doses)
Trial: 11438132
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg for 14 days
Trial: 2551355
Drug: 2-drug chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-4 and vincristine 1 mg i.v. days 1 + 4; every 4 weeks)
Trial: 2551355
Drug: 4-drug chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-3, vincristine 2 mg i.v. day 1 and 1 mg i.v. day 5, methotrexate 30 mg i.v. days 3 and 5, CCNU 80 mg/m2 i.v. day 2; every 7 weeks)
Trial: 332438
Drug: Trimazosin, 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin, 900 mg daily
Trial: 332438
Drug: Methyldopa, 2,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa, 2,250 mg daily
Trial: 31587885
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg intravenously)
Trial: 23275404
Drug: 5 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 weekly doses of milieu communication teaching (MCT)
Trial: 23275404
Drug: 1 weekly
RxNorm normalized name: granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 weekly dose of milieu communication teaching (MCT)
Trial: 19517231
Drug: Havrix (HAV)
RxNorm normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havrix (HAV) vaccine
Trial: 19517231
Drug: TWINRIX (HAV/HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TWINRIX (HAV/HBV combination vaccine)
Trial: 19517231
Drug: Engerix (HBV)
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix (HBV) vaccine